Jongkonnee - Thanasai

Dr. Jongkonnee - Thanasai

orcid
Faculty of Medicine, Mahasarakham University , THAILAND

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Jongkonnee - ThanasaiJongkonnee - Thanasai
Jongkonnee - Thanasai
To evaluate the role of thymidine phosphorylase (TP) in cholangiocarcinoma using small interfering RNA (siRNA). A human cholangiocarcinoma-derived cell line KKU-M139, which has a naturally high level of endogenous TP, had TP expression transiently knocked down using siRNA. Cell growth, migration, in vitro angiogenesis, apoptosis, and cytotoxicity were assayed in TP knockdown and wild-type cell lines. TP mRNA and protein expression were decreased by 87.1% + or - 0.49% and 72.5% + or - 3.2%, respectively, compared with control cells. Inhibition of TP significantly decreased migration of KKU-M139, and suppressed migration and tube formation of human umbilical vein endothelial cells. siRNA also reduced the ability of TP to resist hypoxia-induced apoptosis, while suppression of TP reduced the sensitivity of KKU-M139 to 5-fluorouracil. Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy.

1 January 2006 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Jongkonnee - ThanasaiJongkonnee - Thanasai
Jongkonnee - Thanasai
TLTemduang Limpaiboon
Temduang Limpaiboon
PJPatcharee Jearanaikoon
Patcharee Jearanaikoon
VBVajarabhongsa Bhudhisawasdi
Vajarabhongsa Bhudhisawasdi
NKNarong Khuntikeo
Narong Khuntikeo
MMMasanao Miwa
Masanao Miwa
AIM: To analyze the DNA copy number of target genes NF2, TIMP3, ST13, TOB2, BIK, and TP and the reference microsatellite markers D22S283, D22S423, and D22S274 mapped on 22q12-qter in liver fluke related cholangiocarcinoma (CCA) and define its correlation with clinical parameters. METHODS: Quantitative real time PCR (qPCR) was used for determining allelic imbalances in 65 liver fluke related CCA tissues. Statistical correlations between allelic imbalances and clinicopathological parameters, i.e. age, sex, tumor stage, histological type, blood vessel invasion, nerve invasion and lymphatic invasion were evaluated by means of the χ2 test. Cox regression analysis was used for determining patient’s survival. RESULTS: Amplifications of the TP (22q13.33), TOB2 (22q13.2-13.31), D22S283 (22q12.3), TIMP3 (22q12.3) and NF2 (22q12.2) were found in 35 (53.8%), 28 (43.1%), 27 (41.5%), 24 (36.9%), and 24 (36.9%), respectively. Losses at the D22S423 (22q13.1-13.2) and BIK (22q13.31) were detected in 26 (40%) and 23 (35.4%), respectively. Significant correlations were observed between lymphatic invasion and allelic losses of BIK (P = 0.025) and D22S283 (P = 0.041). Univariate and multivariate Cox regression analysis revealed D22S283 amplification as an independent predictor of good prognosis (P = 0.006, death hazard ratio = 0.411, 95% CI = 0.217-0.779) and blood vessel invasion as an independent poor prognostic factor (P = 0.042, death hazard ratio = 1.911, 95% CI = 1.022-3.571) in CCA patients. CONCLUSION: This study provides evidence for the involvement of gene amplification and deletion on chromosome 22q in liver fluke related CCA. This is the first report of D22S283 amplification as an independent indicator of favorable prognosis in liver fluke related CCA.

JSJirarat Songsri
Jirarat Songsri
Jongkonnee - ThanasaiJongkonnee - Thanasai
Jongkonnee - Thanasai
JTJitbanjong Tangpong
Jitbanjong Tangpong
ACAnchalee Chittamma
Anchalee Chittamma
Wiyada Kwanhian KlangbudWiyada Kwanhian Klangbud
Wiyada Kwanhian Klangbud
Background: The early diagnosis of pulmonary tuberculosis (PTB) remains a global challenge. While serum adenosine deaminase (ADA) has been associated with tuberculosis-related immune activation, its consistency across different regions and laboratory methods remains unclear. This study aims to evaluate group-level differences in serum ADA levels and identify factors influencing these variations. Methods: A systematic search was conducted across PubMed, Embase, and Scopus up to February 2026. A meta-analysis using a random-effects model was performed to calculate the pooled standardized mean difference (SMD), reflecting group-level differences in serum ADA levels between PTB patients and control groups. Results: Thirty-four studies were included. Serum ADA levels were significantly higher in PTB patients compared to healthy controls (SMD = 3.15, 95% CI: [2.51–3.79], p < 0.0001) and other respiratory diseases (SMD = 2.06, 95% CI: [1.38–2.74], p < 0.0001). Subgroup analyses revealed that geographical region and ADA measurement methods did not significantly account for the observed high heterogeneity (I2 > 95%), indicating that ADA elevation was consistently observed across studies. Conclusions: Serum ADA levels were significantly elevated in patients with PTB, indicating a consistent biological association with disease status. However, given the high heterogeneity and the absence of diagnostic accuracy measures (e.g., sensitivity and specificity), these findings should not be interpreted as evidence of clinical diagnostic performance. Further diagnostic test accuracy studies are required to establish its clinical utility.

25 June 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Jongkonnee - ThanasaiJongkonnee - Thanasai
Jongkonnee - Thanasai
SLSa-ngob Laklaeng
Sa-ngob Laklaeng
SKSupphachoke Khemla
Supphachoke Khemla
KRKhonesavanh Ratanavong
Khonesavanh Ratanavong
Moragot ChatatikunMoragot Chatatikun
Moragot Chatatikun
Wiyada Kwanhian KlangbudWiyada Kwanhian Klangbud
Wiyada Kwanhian Klangbud
Background: Burkholderia pseudomallei, the causative agent of melioidosis, is intrinsically resistant to multiple antibiotics, posing substantial challenges for treatment. Reports of acquired resistance are increasing, underscoring the need for global surveillance. Objective: This systematic review and meta-analysis aimed to determine the global prevalence of antibiotic-resistant B. pseudomallei isolated from human clinical cases, with a focus on regional differences and variations in antimicrobial susceptibility testing methods. Methods: We systematically searched PubMed, Scopus, and Embase for studies reporting resistance in clinical B. pseudomallei isolates, following PRISMA guidelines. Pooled resistance rates to 11 antibiotics were calculated using a random-effect model. Subgroup analyses were performed based on geographical region and testing methodology (MIC vs. disk diffusion). Results: Twelve studies comprising 10,391 isolates were included. Resistance rates varied across antibiotics, with the highest pooled resistance observed for tigecycline (46.3%) and ciprofloxacin (38.3%). Ceftazidime (CAZ) and trimethoprim–sulfamethoxazole (SXT), commonly used first-line agents, showed resistance rates of 5.3% and 4.2%, respectively. Subgroup analyses of CAZ and SXT revealed significantly higher resistance in studies from Asia compared to Australia and America (p value < 0.0001). Disk diffusion methods tended to overestimate resistance compared to MIC-based approaches, which revealed non-significant differences for CAZ (p value = 0.5343) but significant differences for SXT (p value < 0.0001). Conclusions: Antibiotic resistance in B. pseudomallei exhibits regional variation and is influenced by the susceptibility testing method used. Surveillance programs and standardized antimicrobial susceptibility testing protocols are essential to guide effective treatment strategies and ensure accurate resistance reporting.

Jongkonnee - ThanasaiJongkonnee - Thanasai
Jongkonnee - Thanasai
APAtthaphong Phongphithakchai
Atthaphong Phongphithakchai
Moragot ChatatikunMoragot Chatatikun
Moragot Chatatikun
SLSa-ngob Laklaeng
Sa-ngob Laklaeng
JTJitbanjong Tangpong
Jitbanjong Tangpong
Wiyada Kwanhian KlangbudWiyada Kwanhian Klangbud
Wiyada Kwanhian Klangbud
Background: Travel-associated melioidosis, caused by Burkholderia pseudomallei, is increasingly reported in non-endemic countries due to rising global travel. Understanding demographic, clinical, and outcome patterns of imported cases is important to improve recognition and management in settings where melioidosis is uncommon. Methods: We systematically searched PubMed, Embase, and Scopus (last search: 24 September 2025) for case reports and case series of melioidosis diagnosed outside endemic regions and linked to travel exposure. Data were extracted on demographics, comorbidities, clinical manifestations, and outcomes. We performed descriptive analyses, subgroup analyses, and Firth’s penalized logistic regression to explore predictors of death. The protocol was registered in PROSPERO (CRD420251154559). Results: A total of 104 studies, encompassing 143 individual cases, were included. Most diagnoses occurred in non-endemic, high-income countries, especially the Netherlands (21%), France (10%), the United States (9%), and South Korea (7%). Infections were predominantly acquired in Southeast Asia, particularly Thailand (39%). The mean patient age was 50.6 years, with a male predominance (78%). Diabetes mellitus was the most frequent comorbidity (28%). Clinical presentations included pulmonary (33%), sepsis (27%), cutaneous (13%), abdominal (4%), and osteoarticular disease (1%). Overall mortality was 12.6% and relapse occurred in 7%. In penalized regression analyses, no baseline characteristic was statistically significantly associated with mortality; septic presentation showed an elevated point estimate for odds of death, but with imprecise estimates. Conclusions: Travel-associated melioidosis is a rare but clinically significant imported infection. Most cases followed exposure in Southeast Asia, and pulmonary disease and sepsis were the most frequent presentations. Mortality remained substantial (12.6%), and relapse was reported in 7%, underscoring the need for early recognition, appropriate therapy, and follow-up in non-endemic settings.

7 April 2026 in Foods
Verified
Journal Article
Open access
PDF file
Moragot ChatatikunMoragot Chatatikun
Moragot Chatatikun
ATAman Tedasen
Aman Tedasen
CJChutima Jansakun
Chutima Jansakun
PPPassakorn Poolbua
Passakorn Poolbua
JHJason Huang
Jason Huang
APAtthaphong Phongphithakchai
Atthaphong Phongphithakchai
Alpha-mangostin (AM), a xanthone from Garcinia mangostana, has shown promising nephroprotective properties, but its mechanisms in acute kidney injury (AKI) remain incompletely defined. In this study, we applied an integrative network pharmacology pipeline combined with molecular docking to clarify AM’s multi-target mechanisms in AKI. We identified 128 predicted AM targets and intersected them with AKI-related genes, yielding 122 shared targets. Protein–protein interaction analysis identified ten hub genes—TNF, AKT1, IL6, SRC, CTNNB1, HSP90AA1, NFKB1, HIF1A, PPARG, and PTGS2—implicating inflammatory, hypoxia, and cell-survival pathways. KEGG enrichment highlighted HIF-1 signaling, PI3K–Akt signaling, chemokine signaling, AGE–RAGE signaling, and pathways related to cellular senescence and oxidative stress, while GO terms emphasized responses to chemical/oxygen-containing compounds, kinase activity, signal transduction, and apoptosis. Molecular docking against the ten hub proteins showed favorable binding energies across multiple targets. The strongest predicted affinities were observed for PTGS2 (−11.13 kcal/mol), TNF (−9.74 kcal/mol), and AKT1 (−9.48 kcal/mol). Docking positioned AM within the COX-2 catalytic pocket, engaging key catalytic and hydrophobic residues similar to known inhibitors. MD simulation interaction analysis confirmed that AM maintained stable contacts with key human PTGS2 residues, characterized by dominant hydrogen bonds and water-bridge interactions with SER353, TYR355, ARG513, and SER530, along with consistent hydrophobic contacts, and persistent interactions sustained throughout the 200 ns trajectory. Collectively, these results suggest that AM modulates interconnected inflammatory, hypoxic, and survival pathways relevant to AKI, acting as a multi-target ligand with notable interaction involving COX-2, TNF, and AKT1. Further experimental validation and formulation strategies to improve bioavailability are recommended for the advancement of AM toward therapeutic evaluation in AKI.